Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Information technology (IT) products distributor, Tech Data Corp. ( TECD - Analyst Report ) reported dismal third quarter 2013 results with earnings of $1.21 per share missing the Zacks Consensus Estimate of $1.33. Reported revenue also missed the consensus mark of $6.21 billion.
Quarter Details
Total revenue declined 8.4% year over year to $6.04 billion. Foreign currency fluctuations negatively impacted revenue by 5% in the reported quarter. Moreover, revised representation of sales of vendor warranty services and certain fulfillment contracts had a 3.0% negative impact on the quarter’s result.
Net sales in North America and Latin America (representing 39.0% of total sales) plunged 15.0% to $2.37 billion. Net sales in Europe (representing 61.0% of total sales) decreased 4.0% to $3.67 billion.
Gross profit decreased 10.6% year over year to $308.3 million. Gross margin was 5.10% compared with 5.23% in the prior-year quarter. The year-over-year decline was primarily due to unfavorable product mix, customer mix and competitive pricing conditions in certain markets during the quarter.
Selling, general & administrative (SG&A) expenses decreased 6.5% year over year to $238.7 million in the reported quarter. This year-over-year decline was due to weakness in euro and cost improvements resulting from business shutdown in Brazil and Colombia.
However, operating income plunged 22.4% year over year to $69.5 million, primarily due to lower revenue base. Operating margin was 1.15% compared with 1.36% reported in the year-ago quarter.
Geographically, operating income in the Americas was $33.7 million versus $52.6 million in the year-ago quarter. Operating margin in the region was 1.43% compared with 1.89% in the year-ago quarter. Operating income in Europe was $39.4 million or 1.07% of net sales versus $39.7 million or 1.04% of net sales in the year-ago quarter.
Net income was $45.9 million or $1.21 per share compared with $53.5 million or $1.26 per share in the prior-year quarter.
At quarter end, Tech Data had approximately $515.8 million in cash compared with $277.6 million in the previous quarter. Cash provided by operations during the quarter totaled $33.1 million.
Outlook
For the fourth quarter, Tech Data expects year-over-year sales growth in the range of low-single-digit. Gross and operating margins are expected to increase on a sequential basis. Tech Data expects year-over-year sales growth of low-single-digits in Europe (in €). In Americas, sales are expected to decrease in the low-double digit range.
Recommendation
We believe that Tech Data’s strategy of shifting resources from lower-performing regions to higher-growth regions, cost reductions (shutting down business in the loss-making Brazilian and Colombian units) and accretive acquisitions (14 acquisitions added $1.5 billion in sales over the last four years) will drive growth over the long term.
Tech Data, which distributes products manufactured by Apple Inc. ( AAPL - Analyst Report ) and Hewlett-Packard Co. ( HPQ - Analyst Report ) , expects IT spending to remain sluggish in fiscal 2013. We believe that Tech Data faces a number of headwinds in the near term, including a volatile European market (approximately 60.0% of revenue) as well as lack of visibility in government spending in the U.S.
Sluggish PC shipments are also expected to hurt Tech data’s top-line growth. Tech Data derives approximately 15% – 20% of revenue from PC distribution.
We, thus, maintain our long-term Neutral recommendation on the stock. Currently, the stock has a Zacks #3 Rank, implying a short-term Hold rating.
Read the full reports :
Analyst Report on TECD
Analyst Report on AAPL
Analyst Report on HPQ